Researchers analyzed 727 pancreatic cancer patients who received neoadjuvant therapy and pancreatectomy from 1998 to 2018. They found an increase in neoadjuvant chemotherapy use and a shift in the timing of recurrence risk from postoperative year 1 to year 2. Overall survival improved over time, predominantly due to better post-recurrence survival rates. Recurrence rates remained stable, with most recurrences occurring within 2 years. The study highlights improved survival outcomes with modern multimodality regimens for pancreatic cancer.
Journal Article by Cass SH, Tzeng CD (…) Ikoma N et 11 al. in Ann Surg
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.